Biotech 2050 Podcast cover image

Biotech 2050 Podcast

Transforming the treatment of neuromuscular diseases, James McArthur, CEO, PepGen

Aug 23, 2023
James McArthur, CEO of PepGen, discusses his venture capital experience and how it influences his management style. He explores drug development in rare diseases, particularly neuromuscular diseases. He highlights the importance of multiple treatment options and patient organizations. He also talks about adapting to a changing environment during the pandemic and the value of surrounding oneself with good people.
28:13

Episode guests

Podcast summary created with Snipd AI

Quick takeaways

  • Building successful teams and aligning with investors who share the vision are crucial for company building and solving problems in the biotech industry.
  • Deep engagement with the rare disease community, including patients, families, and patient organizations, is essential for effective drug development in this space.

Deep dives

James MacArthur's Journey in Biotech

James MacArthur, president and CEO of Pepc gen, shares his journey in the biotech industry. He started his career in academia but by chance got introduced to the field of gene therapy, which allowed him to combine his background in immunology, biochemistry, and psychology. Over the years, he has worked in various companies, focusing on translating scientific discoveries into therapies that help people. He highlights the importance of building teams that are successful in solving problems and bringing together investors who share the vision of improving patients' lives.

Remember Everything You Learn from Podcasts

Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
App store bannerPlay store banner